| abstract |
A cellular model with a highly glycolytic phenotype (L929dt cells) for study of phosphaplatin-based anticancer agents, in particular (R,R)-1,2-cyclohexanediamine-(pyrophosphato) platinum(II) (or "PT-112"), is disclosed. The expression of HIF-1α as a biomarker of glycolytic cells sensitive to PT-112, clinical applications of the biomarker, and methods thereof for diagnosis and treatment of patients with cancers are disclosed. |